Twist Bioscience Reports Q3 GAAP EPS Miss and Revenue Beat
In its third-quarter financial report, Twist Bioscience (NASDAQ: TWST) reported a GAAP earnings per share (EPS) of -$0.56, which missed the expected figure by $0.08. However, revenue came in at $118.4 million, surpassing estimates by $3.86 million and showing year-over-year growth of 23.2%. The company's performance highlights a mixed quarter with strong top-line results but disappointing earnings. For the full fiscal year 2026, Twist Bioscience expects total revenue to range between $456 million and $457 million, slightly above the current consensus estimate of $444.69 million. This guidance suggests continued confidence in future growth despite the Q3 earnings shortfall. The results reflect ongoing challenges for biotech firms navigating market volatility while maintaining strong operational momentum.
Tickers: $TWST
Topics: Earnings EPS Miss Revenue Beat